Three Changes Coming to Drug Pricing

Here are three solid bets for pharma companies to plan for in the changing drug-pricing landscape.

Read the Full MedCity News Byline

Chance Scott discusses how pharma needs to remain nimble on price reform to ensure recoupment of investment and funding of future innovation. He explains why the Biden Administration’s pause on implementing new federal drug policies is not a time to be wasted. It’s time for pharma to be realistic about where regulation seems to be headed and draw up the plans now to prevent dire surprises.

What pharma companies should be prepared for:

  • Ending some financial incentives
  • Request for transparency, even if non-informative
  • A focus on value

Read more in his MedCity News byline.

About the Experts

Back to top